Anticoagulant

APIXABAN (BD-PIXA) Tablet

$96.00

However, its use requires careful oversight by healthcare providers, with vigilant monitoring for adverse effects and therapeutic response. With ongoing research and clinical advancements, apixaban continues to revolutionize anticoagulation therapy, providing hope and healing to countless individuals affected by thromboembolic disorders.

Strength	Choose an option2.5mg5mg
	Clear

Quantity

APIXABAN (BD-PIXA) Tablet quantity

Add to cart

Sku:

N/A

Tag:

APIXABAN BD-PIXA

Description

Apixaban (BD-PIXA) Tablet is an oral anticoagulant medication used for the prevention of blood clots in patients with various medical conditions. It belongs to the class of direct oral anticoagulants (DOACs) and specifically inhibits factor Xa, a key enzyme in the coagulation cascade, thereby preventing the formation of blood clots.

Key Features:

• Factor Xa Inhibitor: Apixaban inhibits the activity of factor Xa, a pivotal enzyme in the coagulation cascade that converts prothrombin to thrombin, thus preventing the formation of fibrin clots. By targeting factor Xa directly, apixaban provides effective anticoagulation with predictable pharmacokinetics and pharmacodynamics.
• Prevention of Blood Clots: Apixaban (BD-PIXA) Tablet is indicated for various medical conditions requiring anticoagulation, including the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF), treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery.
• Oral Administration: Apixaban (BD-PIXA) Tablet is administered orally, typically once or twice daily, with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Fixed-Dose Formulation: Apixaban is available in fixed-dose formulations, eliminating the need for dose adjustment based on laboratory monitoring. However, dose adjustments may be necessary in certain patient populations, such as those with renal impairment or concomitant use of interacting medications.
• Efficacy: Clinical trials have demonstrated the efficacy of apixaban in reducing the risk of stroke and systemic embolism in patients with NVAF, preventing recurrent DVT and PE, and reducing the risk of VTE in patients undergoing hip or knee replacement surgery. It has shown comparable or superior efficacy to traditional anticoagulants like warfarin with a lower risk of bleeding complications.
• Safety Profile: Apixaban generally has a favorable safety profile with a lower risk of bleeding complications compared to warfarin. However, like all anticoagulant medications, it may increase the risk of bleeding, and patients should be closely monitored for signs of bleeding during treatment.
• Patient Education: Patients prescribed Apixaban (BD-PIXA) Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. They should also be educated about signs of bleeding and when to seek medical attention.
• Consultation with Healthcare Provider: Treatment with Apixaban (BD-PIXA) Tablet should be initiated and monitored by a qualified healthcare provider experienced in the management of anticoagulation therapy. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Apixaban (BD-PIXA) Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to effective anticoagulant therapy is crucial for preventing thrombotic events and improving patient outcomes.

Additional information